FGFR3 and TP53 gene mutations define two distinct pathways in urothelial cell carcinoma of the bladder.
FGFR3 and TP53 mutations are frequent in superficial papillary and invasive disease, respectively. We used denaturing high-performance liquid chromatography and sequencing to screen for FGFR3 and TP53 mutations in 81 newly diagnosed urothelial cell carcinomas. Tumors were classified as follows: 31 pTa, 1 carcinoma in situ, 30 pT1, and 19 pT2-T4. Tumor grades were as follows: 10 G1, 29 G2, and 42 G3. FGFR3 mutations were associated with low-stage (P < 0.0001), low-grade (P < 0.008) tumors, whereas TP53 mutations were associated with high-stage (P < 0.003), high-grade (P < 0.02) tumors. Mutations in these two genes were almost mutually exclusive. Our results suggest that FGFR3 and TP53 mutations define separate pathways at initial diagnosis of urothelial cell carcinoma.
Bakkar
Ashraf A
AA
Equipe mixte Inserm Institut National de la Santé et de la Recherche Médicale, and Service d'Urologie, Paris, France.
Wallerand
Herve
H
Radvanyi
François
F
Lahaye
Jean-Baptiste
JB
Pissard
Serge
S
Lecerf
Laure
L
Kouyoumdjian
Jean Claude
JC
Abbou
Claude C
CC
Pairon
Jean-Claude
JC
Jaurand
Marie-Claude
MC
Thiery
Jean-Paul
JP
Chopin
Dominique K
DK
de Medina
Sixtina Gil Diez
SG
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002295:Carcinoma, Transitional Cell / Q000235:genetics* / Q000473:pathology; D016158:Genes, p53 / Q000235:genetics*; D006801:Humans; D008875:Middle Aged; D009154:Mutation; D009367:Neoplasm Staging; D011505:Protein-Tyrosine Kinases; D051498:Receptor, Fibroblast Growth Factor, Type 3; D017468:Receptors, Fibroblast Growth Factor / Q000235:genetics*; D001749:Urinary Bladder Neoplasms / Q000235:genetics* / Q000473:pathology
D017468:Receptors, Fibroblast Growth Factor; C496365:FGFR3 protein, human; D011505:Protein-Tyrosine Kinases; D051498:Receptor, Fibroblast Growth Factor, Type 3